Publicaciones en las que colabora con Jorge Arca-Suarez (15)

2023

  1. Pseudomonas aeruginosa antibiotic susceptibility profiles, genomic epidemiology and resistance mechanisms: a nation-wide five-year time lapse analysis

    The Lancet Regional Health - Europe, Vol. 34

  2. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 5, pp. 1195-1200

2022

  1. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 10, pp. 2809-2815

2021

  1. Caracterización molecular del desarrollo de resistencia in vivo a las nuevas combinaciones de cefalosporina/inhibidor de β-lactamasa durante el tratamiento de infecciones por pseudomonas aeruginosa multirresistente

    Caracterización molecular del desarrollo de resistencia in vivo a las nuevas combinaciones de cefalosporina/inhibidor de β-lactamasa durante el tratamiento de infecciones por pseudomonas aeruginosa multirresistente

  2. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 1, pp. 91-100

2020

  1. First identification of blaNDM-1 carbapenemase in blaOXA-94-producing Acinetobacter baumannii ST85 in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 1, pp. 11-15

  2. HIV antibodies level as a marker of HIV persistence: the role of hepatitis C virus coinfection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 39, Núm. 8, pp. 1503-1512

  3. Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

    The Journal of antimicrobial chemotherapy, Vol. 75, Núm. 11, pp. 3209-3217

2019

  1. Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 10

  2. Co-Occurrence of mcr-1 and qnrS1 on an IncHI2 Plasmid in Clinical Isolates of Salmonella Typhimurium in Spain

    Vector-Borne and Zoonotic Diseases, Vol. 19, Núm. 9, pp. 662-665

  3. Staphylococcus aureus carriage in older populations in community residential care homes: Prevalence and molecular characterization of MRSA isolates

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 172-175

2018

  1. Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates from Spain and molecular characterisation of borderline susceptible and resistant strains

    Journal of Global Antimicrobial Resistance

  2. Antimicrobial susceptibility and molecular typing of toxigenic clinical isolates of Clostridium difficile causing infections in the south of Spain

    Anaerobe, Vol. 54, pp. 146-150

2017

  1. A modified ESBL Nordmann/Dortet/Poirel-based protocol to optimize early sepsis management

    Journal of Microbiological Methods, Vol. 139, pp. 45-47

  2. Direct identification of microorganisms from thioglycolate broth by MALDI-TOF MS

    PLoS ONE, Vol. 12, Núm. 9